A Multicenter, Open-label, Phase 2, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects With Relapsed or Refractory or de Novo Diffuse Large B-cell Lymphoma (DLBCL)
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To measure the number of patients with a response to study drug
Participants will be followed until progression of disease or start of another anti-cancer treatment.
24 weeks from first dose
No
Darrin Beaupre, MD
Study Director
Pharmacyclics
United States: Food and Drug Administration
PCYC-1106-CA
NCT01325701
May 2011
June 2014
Name | Location |
---|---|
Mayo Clinic | Rochester, Minnesota 55905 |
Memorial Sloan-Kettering Cancer Center | New York, New York 10021 |
University of Nebraska Medical Center | Omaha, Nebraska 68198-3330 |
Hackensack University Medical Center | Hackensack, New Jersey 07601 |
Weill Medical College of Cornell University | New York, New York 10021 |
Long Island Jewish Medical Center | New Hyde Park, New York 11040 |
Stanford University School of Medicine | Stanford, California 94305-5317 |
UCLA Medical Center | Los Angeles, California 90095-7059 |
New York University | New York, New York 10016 |
University of Wisconsin | Madison,, Wisconsin 53792-5666 |
The University of Texas MD Anderson Cancer Center | Houston, Texas 77030-4009 |
National Cancer Institute | Bethesda, Maryland 20892-1922 |
University of Rochester School of Medicine and Dentistry | Rochester, New York 14642 |
The Ohio Sate university | Columbus, Ohio 43210 |
Univerity of Washington | Seattle, Washington 98109 |